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 Abstract 
Purpose: 
The goals of the study were to elucidate the immune mechanisms that contribute to 
desirable complete remissions of murine colon tumors treated with single radiation dose 
of 30 Gy. This dose is at the upper end of the ablative range used clinically to treat 
advanced or metastatic colorectal, liver, and non-small cell lung tumors.  
 Experimental design: 
Changes in the tumor immune microenvironment of single tumor nodules exposed to 
radiation were studied using 21 day (>1 cm in diameter) CT26 and MC38 colon tumors. 
These are well-characterized weakly immunogenic tumors.  
 Results: 
 We found that the high dose radiation transformed the immunosuppressive tumor 
microenvironment resulting in an intense CD8+ T cell tumor infiltrate, and a loss of 
myeloid derived suppressor cells (MDSCs). The change was dependent on antigen cross-
presenting CD8+ dendritic cells, secretion of IFN- γ, and CD4+T cells expressing CD40L.  
Anti-tumor CD8+ T cells entered tumors shortly after radiotherapy, reversed MDSC 
infiltration, and mediated durable remissions in an IFN-γ dependent manner. 
Interestingly, extended fractionated radiation regimen did not result in robust CD8+ T cell 
infiltration. 
Conclusion: 
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 For immunologically sensitive tumors, these results indicate that remissions induced by a 
short course of high dose radiation therapy depend on the development of anti-tumor 
immunity that is reflected by the nature and kinetics of changes induced in the tumor cell 
microenvironment. These results suggest that systematic examination of the tumor 
immune microenvironment may help in optimizing the radiation regimen used to treat 
tumors by adding a robust immune response.  
 Translational relevance 
The results of the study can provide information to optimize the efficacy of radiotherapy 
used alone or in combination with immunotherapy. These results suggest that for clinical 
trials of immune stimulation by radiotherapy alone or in combination with 
immunotherapy the high dose regimen should be rapid rather than extended for at least 
some tumors.  
Introduction 
 Due to recent advances in image guidance and radiation treatment delivery techniques, 
single ablative doses as high as 30Gy can be safely delivered to many tumor sites by a 
procedure known as stereotactic radiosurgery (SRS), stereotactic body radiation therapy 
(SBRT), or stereotactic ablative body irradiation (SABR)(1-5). High total doses of 
radiation achieved by a single treatment (extreme oligofractionation), or by 2 to 5 high 
dose treatments (oligofractionation or hypofractionation) have been used as an alternative 
to conventional daily low dose fractionated treatments (<3Gy) over several weeks. 
Limited clinical results show improved efficacy compared with fractionated radiotherapy 
in managing advanced or metastatic colorectal, liver, and non-small cell lung tumors. The 
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outcome can be comparable to that of surgery for resectable tumors, and SRS can be 
applied to unresectable tumors (2, 3).  Also, new radiation regimens are proposed that can 
deliver radiation in short pulses at ultrahigh dose rates while minimizing normal tissue 
injury (FLASH)(4). 
 The goal of the current study was to systematically examine the role of tumor immunity 
in a mouse model in which high-dose, single fraction tumor radiation induces complete 
durable remissions. We used the CT26 and MC38 colon tumors, since they are well-
characterized (6-8). Although these tumors express retroviral encoded antigens, they are 
weakly immunogenic, and vaccination with irradiated tumor cells fails to induce immune 
responses that protect against tumor growth after subsequent tumor challenge (9).  
Large CT26 tumors as well as other advanced solid tumors can evade anti-tumor 
immunity partly by promoting the development of an immunosuppressive/tolerogenic 
microenvironment that includes regulatory cells such as myeloid derived suppressor cells 
(MDSCs), tumor associated macrophages (TAMs), and regulatory CD4+ T cells 
(Tregs)(10-15).  In addition, the conventional T cells in the tumor infiltrate are 
dysfunctional due the expression of negative co-stimulatory receptors such as PD-1 and 
Tim-3 that can interact with ligands such as PDL-1 and galectin-9 on tumor or stromal 
cells (13). A high percentage of suppressive myeloid cells and/or expression of negative 
co-stimulatory receptors and their ligands predict an unfavorable outcome for patients 
with a variety of cancers including colorectal cancers, and a high percentage of 
infiltrating conventional CD8+ T cells predicts a favorable outcome of cancers(16-19).  
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 Radiotherapy can be curative not only by killing tumor cells and their associated stromal 
and vascular cells, but also by inducing T cell immunity (12, 20-27).  The anti-tumor T 
cell immunity can induce remissions at distant sites from the radiated tissues (“abscopal” 
effect) alone or in combination with immunotherapy (27-31). Radiation induced injury 
causes release of tumor antigens, activation of dendritic cells, and stimulation of CD8+ T 
cell immunity by the production of innate immune stimuli including the TLR-4 agonist, 
high-mobility group protein 1 (HMGB), as well as type I interferons, adenosine 
triphosphate (ATP), and calreticulin (32-38).  
We found that the immunosuppressive microenvironment in the tumors was altered by a 
single 30Gy dose of radiation that rapidly increased the infiltration of CD8+ tumor killing 
T cells. Infiltration of the latter was dependent on the CD8+ subset of antigen cross 
priming dendritic cells, help via CD40L on CD4+ T cells, and CD8+ T cell production of 
IFN-γ.  The CD8+ T cells eliminated MDSCs in the stroma, and induced remissions.  
Materials and Methods 
Animals Wild-type male BALB/c (H-2d) and C57BL/6 (H-2b) mice, BALB/c RAG2-/-, 
BALB/c Batf3-/- mice, were purchased from Jackson Laboratories (Bar Harbor, ME). The 
Stanford University Committee on Animal Welfare (APLAC) approved all mouse 
protocols used in this study.  
Cell lines The CT26 cell line was purchased from ATCC (Manassas, VA). CT26 –
LUC/GFP cell line was transduced as described previously (39-41).  
 The MC38 cell line was provided by D. Bartlett (University of Pittsburgh, Pittsburgh, 
PA). All cell lines were authenticated according ATCC cell line authentication test 
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recommendations that included a morphology check by microscope, growth curve 
analysis, and standard Mouse Pathogen PCR Panel 1 to rule out mycoplasma infection 
(performed 06/24/09).  
Irradiation 
 Irradiation was performed with a Phillips X-ray unit operated at 200 kV with the dose 
rate of 1.21 Gy/min (2.0 mm aluminum with added filtration of 0.5 mm copper, the 
distance from X-ray source to the target of 31 cm, and a half value layer of 1.3 mm 
copper) The unanesthetized mice were placed in individual lead boxes with a cutout that 
allowed the tumor to be irradiated tangentially with full shielding of the the rest of the 
body. To ensure the maximum uniformity of the dose delivered, the animals were turned 
by 180° half way through each irradiation (giving the equivalent of parallel opposed 
fields). This ensures that the dose inhomogeneity within the tumor from edge to center is 
less than 2%. The depth dose is defined by the half value layer, which is 7.5 cm. The dose 
to the skin was 100% of the tumor dose and we did not see significant skin reactions 
other than late scarring and contraction (42).   
 
Analysis of tumor infiltrating cells 
 
In order to analyze percentages among mononuclear cells, Collagenase D (Roche, 
11088882001) was used to digest tumors for 25 minutes, and a single cell suspension was 
layered over 3 ml Lympholyte M (CL5030, Cedarlane), a well-defined layer of 
mononuclear cells was collected. Cells were stained with fluorochrome conjugated 
monoclonal antibodies (mAbs) and analyzed by flow cytometry, and correlated with 
histopathology as described previously (9, 43).  In order to determine absolute number of 
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immune cells per mg of tumor, tumor weight was recorded, tumors were digested as 
described above, and the absolute number of cells in the suspension was counted.  
 DC preparation, and T cell depletion 
DCs were isolated from the spleen using the Dendritic Cell Isolation Kit according to the 
manufacturers instructions (130-091-169)(42,43). CD4+ and CD8+ T cells were depleted 
in vivo as by injection of mAbs as described previously (44, 45).  
 MDSC suppression assay 
 MDSCs from 21 day CT26 tumors were isolated using a modification of the MDSC 
isolation kit (Miltenyi Biotech, Auburn CA), in which tumor cells after collagenase 
digestion were stained with biotinilated anti-Gr-1 mAb, and incubated with streptavidin 
microbeads. After column purification, cells were >90% Gr-1 hi CD11b+ as judged by 
flow cytometry (see Supp. Fig. 1F). MDSCs were added to cultures of purified splenic T 
cells labeled with CFSE (Cell Trace, Molecular probes). Proliferation was stimulated 
with anti-CD3/CD28 beads, and cells were analyzed by FACS (9, 46).  
 Statistical analysis 
Kaplan–Meier survival curves were generated using Prism software (SAS Institute Inc., 
Cary, NC), and statistical differences were analyzed using the log-rank (Mantel–Cox) 
test. Survival was defined as the time point after tumor inoculation when the mice were 
euthanized according to veterinary guidelines because they were moribund and unable to 
reach food and/or water, or when the tumor reached a diameter of more than 2cm or 
when the enlarging tumor ulcerated. In some cases, the mice were found dead in their 
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cages. Statistical significance in differences between mean percentages of cells in spleens 
and tumors was analyzed using the two-tailed Student's t-test of means.  
Tumor cell labeling with luciferase 
The  GFP-firefly luciferase fusion (GLF) gene was subcloned from  pJW.GFP-yLuc 
(kindly provided by Dr. M.H. Bachmann) into pHR2 to generate  pHR2-GLF.  293T cells 
were plated in 175  cm2 flasks, and the next day, near-confluent cells were co-transfected 
 with 45 μg lentiviral vector together with packaging and  VSV-G-expressing vectors 
(3:2:1 ratio) in presence of 25 μM  chloroquine (Sigma)(39,40,41). CT26 cells were 
seeded in a 6 well plate at 0.25x106 cells/well and incubated overnight in a 37°C  
incubator. Titrated virus was then used to transduce the cell lines in the presence 
of protamine sulfate (10 μg/ml) to enhance transduction efficiency. Stable lentiviral 
transductants were then sorted 4 times for GFP fluorescence (100% purity) using a FACS 
DIVA cell sorter. Sorted cells were expanded and screened for bioluminescence using 
an Xenogen IVIS spectrum (Caliper Life Sciences; Hopkinton, MA), as well as GFP. Cell 
lines were maintained in RPMI-1640 complete medium supplemented with 10% fetal calf 
serum, L-glutamine, 2 mercaptoethanol, streptomycin and penicillin.   
 
Histopathology 
 Animals were euthanized when moribund as per Stanford Animal Welfare protocol 
guidelines, or at 100 days after transplantation if they survived without morbidity. 
Histopathological specimens were obtained from lungs and livers of hosts. Tissues were 
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fixed in 10% formalin, stained with hematoxylin and eosin and images were obtained 
using an Eclipse E1000M microscope (Nikon, Melville, NY, USA). 
 
 
Results 
The microenvironment of CT26 colon tumors is highly immunosuppressive 
We established CT26 tumors to model advanced disease, and 2.5x104 tumor cells were 
injected subcutaneously into the hind quarter of BALB/c mice, and allowed to grow for 
21 days when the tumor diameter was about 1-1.5 cm. Tumors were excised and the 
mononuclear cells were purified before immunofluorescent staining for T cell markers as 
well as the CD11b and Gr-1 markers of MDSCs and TAMs (47). Figure 1A compares 
representative profiles from the 21day tumors, from spleen cells obtained at the same 
time from the tumor-bearing mice, and spleen cells from untreated normal mice. The 
latter cells were used to show the balance of immune cells in normal lymphoid tissues, 
and normal receptor expression. Whereas the percentage of CD4+ T cells in the tumor-
bearing and normal spleen was about twice as high as CD8+ T cells, in the tumor CD8+ T 
cells were at least twice as high as CD4+ T cells (Fig.1 And B). Among the gated CD8+ 
cells in tumors, about 74% expressed the PD-1+Tim-3+ phenotype that has been described 
for “exhausted” cells in mice with other tumors or with chronic viral infections (13, 48). 
In contrast, among CD8+ T cells in the normal and tumor-bearing spleens, about 5% 
expressed the PD-1+ Tim3+ phenotype. Among the CD4+ cells in tumors, about 33% were 
CD25+, and among the latter, about 60% were FoxP3+ Treg cells (data not shown). In 
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addition, the majority of these CD4+CD25+ and CD4+CD25- T cells expressed the 
negative co-stimulatory receptor, PD-1. Foxp3+ T reg cells were about twice as high 
among CD4+ T cells in tumors as compared to the spleens (Fig. 1A and B). Interestingly, 
the mononuclear cells in tumors contained about 26% CD11b+Gr-1hi cells (MDSC 
phenotype), and 19% that were CD11b+Gr-1lo (TAM phenotype). Tumor-bearing and 
normal spleens contained less than 5 % of each cell type (Fig. 1A and B). MDSC and 
TAM phenotype cells in tumors expressed high levels of PDL-1 (Supp. Fig.2).  
In order to confirm that the CD11b+ Gr-1hi cells in the tumors were capable of immune 
suppression, these cells were purified from the 21 day tumors and assayed for the ability 
to suppress the proliferation of T cells isolated from the normal spleen and stimulated in 
vitro with anti-CD3 and anti-CD28 mAb coated beads. Figure 1C shows representative 
staining patterns of CFSE labeled T cells that were stimulated in the presence or absence 
of an equal number of CD11b+ Gr-1hi cells. Whereas about 68% of T cells expressed low 
levels of CFSE staining in the absence of the CD11b+ Gr-1hi cells, only 1.9% expressed 
low levels after the addition of the latter cells. Alteration of the ratios of the suppressive 
cells to the T cells showed that significant suppression was observed with 1:1 and 1:5 
ratios, but not with ratios of 1:10 or above (Fig.1D). Suppression was no longer 
significant when the CD11b+ Gr1hi cells were separated from T cells in transwells 
(Fig.1C) or when a combination of inhibitors of arginase-1 and iNOS were added to the 
standard wells at 1.5 micromolar concentrations (Fig.1C and E). Thus, the suppressor 
cells required both cell contact and the production of NO and arginase-1 for optimum 
suppression. Based on the above experiments, we used the term “MDSCs” to describe 
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CD11b+Gr1hi phenotype cells, in subsequent experiments reported herein, and did not 
repeat the suppressor assays except when noted.  
 We found no difference in the growth patterns of the primary tumor as compared to the 
growth of the same number of tumor cells injected subcutaneously into the opposite flank 
on day 21 (Fig.1F). In both cases there was a marked increase in volume between days 14 
and 28, and all injected sites grew large tumor nodules. Thus, growth of the first tumor 
does not induce “concomitant” immunity to prevent distant tumor growth at day 21. 
Single high dose radiation of CT26 tumors induces durable complete remissions 
mediated by T cell immunity that can be adoptively transferred 
 In further studies, tumors were given a single dose of 15Gy local tumor irradiation (LTI) 
at day 21 using lead jigs developed for targeting only the 1.0-1.5 cm diameter tumor 
nodule(42) . A complete remission was observed in tumors of 1 of 14 mice and 13 of 14 
did not survive beyond 100 days despite slowing of tumor growth (Fig.2A). Untreated 
tumor-bearing mice did not survive beyond 40 days. When the dose was increased to 
20Gy then 3 of 5 mice developed complete tumor remissions. When the dose was 
increased to 30Gy, 13 of 15 mice achieved complete remissions, and the latter mice 
survived for at least 100 days (Fig. 2A).  Further observations showed no recurrence of 
tumors up to 180 days (data not shown).  
The cured wild type mice observed for 100-150 days were challenged with 
asubcutaneous injection of 5.0x105 CT26 tumor cells, and 9 of 12 tumors resolved after a 
brief increase in volume (Fig 2B). Three out of 12 tumors grew progressively, and mice 
with the latter tumors died within 100 days (Fig.2B). In a previous study(9), we showed 
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that a single subcutaneous vaccination with 1x106 CT26 tumor cells that were irradiated 
in vitro with 50Gy and mixed with the adjuvant, CpG, was able to protect about 50% of  
BALB/c mice from subsequent challenge with 2.5x104 tumor cells. However, when the 
vaccinated mice were challenged with 5.0x105 tumor cells, most tumors grew 
progressively, and about 90% of challenged hosts did not survive (Fig.2B). 
 In order to determine whether T cells from mice with complete remissions of tumors for 
at least 100 days after LTI treatment can adoptively transfer the ability to effectively treat 
CT26 tumors, we used the scheme outlined in the diagram in Fig. 1C. T cells were 
purified from the spleens of the cured mice using anti-Thy1.2 columns, and combined 
with T cell depleted bone marrow cells from the donors. The marrow and T cells were 
injected i.v. into irradiated adoptive recipients that had been given a subcutaneous 
injection of CT26 tumor cells, and then a single dose of 8 Gy TBI 7 days later. The 
tumor- bearing recipients all developed complete remissions and survived for at least 100 
days (Fig.2C). When the experiment was repeated using T cells from the spleen of 
untreated normal mice combined with T cell depleted marrow cells, the adoptive transfer 
did not induce remissions in tumor growth, and all recipients died by day 40 (Fig.1C). 
The survival of the latter recipients was similar to that of recipients given tumors without 
subsequent radiation and transplantation. 
 When mice with 21 day tumors were given 30 Gy LTI at day 21 along with a 
contralateral tumor challenge on the same day, all second tumors grew progressively 
(Fig.2D). In contrast, if challenge was delayed until 30 days after LTI, then only 1 of 5 
second tumors grew progressively. This indicated that there was no “abscopal” effect on 
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second tumor growing simultaneously because systemic tumor immunity did not develop 
immediately after LTI, but become manifest after a few weeks. 
 In order to determine the extent of tumor killing by 30Gy LTI in the absence of T or B 
cells, we used luciferase labeled CT26 cells to establish subcutaneous tumors in RAG2-/- 
BALB/c mice.  Supplementary Figures 3 shows that 30Gy slowed labeled tumor growth, 
but all tumors relapsed, and no tumor bearing mice survived beyond day 70.  
 
High single dose radiation increases CD8+ T cells and reduces MDSCs in the stroma 
of tumors with induced remissions 
The tumor infiltrating mononuclear cells in CT26 tumors given a single dose of 30Gy on 
day 21 were compared to mononuclear cells in unirradiated tumors 14 days later as 
shown in the representative flow cytometry patterns in Figure 3A. Whereas the 
unirradiated tumor mononuclear cells contained about 26% MDSCs and 20% TAMs on 
day 35, the irradiated tumors contained about 6% and 1% respectively. In contrast, the 
unirradiated tumor contained about 19% CD8+ T cells, and the irradiated tumor contained 
about 70%. Thus, the ratio of MDSCs to CD8+ T cells changed from about 1:1 in the 
unirradiated tumor to about 1:10 in the irradiated tumor. Although, the ratios were 
markedly changed, the percentage of CD4+ and CD8+ T cells that expressed high levels 
of Tim-3 and/or PD-1 did not. The change in the composition of tumor infiltrating cells in 
untreated and irradiated mice is clearly seen in the immunofluorescent staining of tumor 
tissue sections for CD11b+ myeloid cells (red) and CD3+ T cells (green) on day 35 (Fig. 
3B). Whereas there is a dense infiltration of myeloid cells with rare T cells in the 
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untreated tumor, there is a dense infiltrate of T cells with rare myeloid cells in the treated 
tumor. 
 Figure 3C shows the kinetics of changes in the mean percentages of MDSCs, TAMs, 
CD11c+ cells (APCs), CD4+ T cells and CD8+ T cells during the 14 day interval after 
30Gy tumor radiation. Interestingly, there was a transient significant rise in the 
percentage of MDSCs that peaked at about 50% three days after LTI (day 24), and then 
fell to below 5% at day 35.  MDSCs that infiltrated the tumor three days after LTI 
retained their suppressive function in vitro (Suppl. Fig. 1 A). The fall in the MDSC 
percentage after day 24 was associated with the significant increase in the percentage of 
CD8+ T cells that began at day 27 and continued until the peak value of about 70% at day 
35. A similar pattern was observed after 15 Gy LTI, but the changes were not as robust as 
with 30 Gy (Supp.Fig.1B). The marked reduction of MDSCs and increase in CD8+ T 
cells in tumor infiltrates during the 14 days after 30 Gy LTI was also observed when the 
mean absolute number of the latter cells per mg of tumor were analyzed (Fig.3D). It is of 
interest that the mean absolute number of live cells per mg of tumor peaked at day 6 after 
LTI, and that the mean tumor weight did not significantly fall until 14 days after LTI 
(Supp.Fig.1 C and D). 
Increased tumor infiltration by CD8+ T cells and reduced infiltration by MDSCs 
after high dose LTI are dependent on cross-presenting CD8+ dendritic cells and 
IFN-γ 
Depletion of either CD8+ or CD4+ T cells by repeated injections of anti-CD8 or anti-CD4 
mAb during the 14 day interval after high dose LTI significantly reduced survival 
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(p<0.001) as compared to non-depleted mice given LTI, and all tumor-bearing hosts 
failed to survive beyond day 73 (Fig.4A). The marked reduction of MDSCs observed 14 
days after LTI (Fig. 3C) was dependent on T cells, since CD8+ or CD4+ depletion resulted 
in a substantial increase in the mean percentage of MDSCs at day 35 as compared to 
irradiated non-depleted hosts (p<0.01) (Fig. 4C). The increase in the percentage of 
MDSCs in T cell depleted mice was not associated with a significant increase (p>0.05) in 
the percentage of TAMs (Fig.4C). Interestingly, the significant increase in the percentage 
of tumor CD8+ T cells 14 days after LTI was not observed with CD4+ T cell depletion 
(Fig. 4C), and indicates that CD4+ T cell help was required. 
We compared the survival of tumor-bearing mice and CD8+ T cell infiltration of tumors 
in wild type BALB/c mice given 30Gy to tumor-bearing Batf3-/- BALB/c mice given 
30Gy. The latter mice have an isolated deficiency of CD8+ antigen cross priming 
dendritic cells (49-51). The latter cells play a critical role in the development of anti-viral 
and anti-tumor immunity by stimulating CD8+ T cells with tumor or viral antigens(23, 
49-52). As shown in Figure 4B, none of the Batf3-/- tumor- bearing mice given 30Gy 
survived more than 60 days, and survival was not significantly different from 
unirradiated mice (p>0.05). These mice failed to show the marked increase in the 
percentage of CD8+ T cells among tumor mononuclear cells at day 35, and the mean 
percentage of CD8+ T cells was below 10% (p<0.001 as compared to wild type mice) 
(Fig.4C). Thus, the tumor infiltration of CD8+T cells and remissions after 30Gy were 
dependent on the presence of CD8+ cross priming dendritic cells. The percentage of the 
cells was significantly increased in the tumors 14 days after LTI (Supp.Fig.1E). These 
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data are consistent with the findings that efficacy of radiotherapy depends on cross-
presenting dendritic cells (23). 
 In further experiments, CD8+CD11c+ DCs were purified from normal spleens, and added 
back to the Batf3-/- tumor-bearing mice given LTI. Figure 4B also shows that the addback 
of the dendritic cells significantly increased the survival of the Batf3-/- mice (p<0.01). The 
increased survival was reflected in a significant increase in the percentage of CD8+ T 
cells among mononuclear cells (p<0.001) in tumors after addback (Fig.4C). Although, the 
TLR-4 receptor on APCs has been reported to play an important role in the induction of 
tumor immunity after radiation or chemotherapy (38), the survival of TLR4-/- tumor-
bearing mice was about 60% at 100 days after 30Gy (Fig.4D). The survival of the latter 
mice did not differ significantly from that of wild type mice (p>0.05), and suggests that 
expression of TLR4 is not required to achieve durable remissions. 
    Since CD8+ T cells that infiltrate tumors can reduce tumor cell growth and increase 
host survival by the production of effector molecules such as IFN-γ, TNF-α, and perforin 
(52-54) we determined the impact of the 30Gy treatment on the survival of IFN-γ-/-, TNF- 
α-/- and perforin-/-mice deficient in each of these molecules. Figure 4D shows that all 
irradiated TNF alpha-/- and perforin-/- tumor-bearing mice survived at least 100 days with 
durable remissions. However, the survival of IFN-γ-/- mice was significantly reduced 
(p<0.01) as compared to the latter mice, and only 20% survived beyond 80 days (Fig.4D). 
Consistent with our earlier findings in mice with tumors that were not irradiated, the poor 
survival of the irradiated IFN-γ-/- mice was associated with a significantly increased 
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percentage of MDSCs in tumors at day 35 as compared to wild type mice (Fig.4C) 
(p<0.01), and a significantly reduced percentage of CD8+ T cells (p<0.05). 
 Daily fractionated radiation does not result in robust CD8+ T cell infiltration 
  The single dose of 30Gy administered to tumors is a model for the clinical use of SRS 
and SBRT. Although tumor control after the single 30 Gy dose administered to 21 day 
CT26 was about 90%, 10 daily radiation doses of 3 Gy each radiation alone resulted in 
the control of only about 10% by day 100 (Fig.5A). Addition of the 10 daily doses of 
3Gy each to the single dose of 30Gy significantly reduced survival (p<0.01) such that 
only 30% of mice had tumor control by day 100 (Fig. 5A). The poor survival of the mice 
given 10 doses of 3Gy each or the combination of 30Gy plus 10 doses of 3Gy was 
associated with a marked reduction in the mean percentage of CD8+ T cells in the tumor 
infiltrate at day35 from about 70% with the single dose alone (Fig.3C) to about 4-8% 
with fractionated radiation alone or in combination with the single high dose (p<0.01) 
(Fig.5B).  
 In addition, the mean percentage of MDSCs in tumors after the combination of single 
and daily doses was increased to about 45% (Fig.5B) as compared to about 5% with the 
single dose alone (Fig.3C)(p<0.01), and about 20% with 10 doses of 3 Gy each (Fig. 5B). 
Interestingly, autopsy of 6 of the 8 mice with the combination that were moribund 
showed the development of metastatic tumor nodules in the lungs in all 6 (Fig.5C), 
whereas none of the autopsies of 8 unirradiated tumor-bearing mice showed lung tumors. 
The difference in survival of mice in the 30 Gy versus 30 Gy+10x3Gy groups is reflected 
in the tumor growth curves shown in Figure 5D. The marked differences in the MDSC 
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and CD8+ T cells infiltration between these groups after treatment is shown by 
comparison of the mean absolute number of cells per mg of tumor (Fig.5E). Although 
SBRT regimen is not combined with daily fractionated radiation in clinic, this experiment 
demonstrates that CD8+T cell infiltration and anti-tumor immunity can be reduced by 
extended radiation. 
 MC38 colon tumors respond to accelerated LTI in a manner similar to CT26 
tumors  
All of the experiments described above examined CT26 tumors growing in BALB/c 
mice.  In further experiments we extended our studies to another colon tumor, MC38, that 
is derived from C57BL/6 mice. The MC38 tumor cells were injected subcutaneously in 
the hind quarter of the latter mice, and nodules grew progressively as described above for 
the CT26 tumor. None of the untreated wild type mice survived more than 35 days, but 
about 80% of those treated with a single dose of 30Gy on day 21 survived at least 100 
days (Fig. 6A).  
 The tumor infiltrating cells in the MC38 tumors showed a pattern similar to that of the 
CT26 tumors at day 35 in unirradiated wild-type mice, since the mean percentage of 
MDSCs ( about 20%) was greater than that of the CD8+ T cells (about 5%) (p<0.01) (Fig. 
6B). There was a significant increase (p<0.001) in the mean percentage of CD8+T cells to 
about 65% at day 35 in the irradiated mice. In contrast to the CT26 studies, the 
percentage of MDSCs in irradiated mice showed no significant decrease as compared to 
unirradiated controls (p>0.05). Interestingly, the CD11c+ cells were the predominant 
mononuclear subset in the unirradiated MC38 tumors, whereas the latter cells were a 
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minor subset in the CT26 tumors. There was a significant reduction in the mean 
percentage of the CD11c+ cells after radiation (Fig. 6B). When TLR4-/- or FasL-/-C57BL/6 
mice were used, instead of wild type mice, about 60% of irradiated tumor-bearing hosts 
survived for at least 100 days, and this was not significantly different from the survival of 
wild type mice (p>0.05) (Fig.6C). In contrast, CD40L-/- irradiated tumor- bearing hosts all 
died by day 70 (Fig.6C). When tumor-bearing hosts were immunodeficient C57BL/6 
RAG-2-/- mice, the efficacy of the radiation treatment was markedly reduced (p<0.01), 
and none of the tumor-bearing mice survived more than 70 days (Fig.6E). Injection of 
RAG2-/- mice with CD4+ and CD8+ T cells from wild-type mice 6 weeks before tumor 
inoculation restored survival of irradiated hosts to more than 80% by 100 days (Fig. 6D 
and E).  
 Injection of CD4+ T cells from CD40L-/- donor mice in combination with CD8+ T cells 
from wild-type mice was less effective in prolonging survival (p<0.01), and only 20% of 
irradiated hosts survived for 100 days (Fig.6D and E). Analysis of day 35 tumor 
infiltrates in the latter hosts showed equal mean percentage (about 25%) of MDSCs and 
CD8+ T cells, instead of the marked imbalance favoring CD8+ T cells in wild type hosts 
(Fig. 6F). The results suggest that CD4+ T cell help for MC38 tumor immunity is 
dependent on CD40L expression on CD4+ T cells. 
 
  
 
Discussion 
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 The goals of the current study were to elucidate the cellular and molecular basis by 
which high-dose, single fraction tumor radiation changes this microenvironment in the 
murine CT26 and MC38 colon tumors. The results of the study can provide information 
to optimize the efficacy of radiotherapy used alone or in combination with 
immunotherapy. SRS with single doses of at least 30 Gy has been suggested to be more 
effective than daily fractionated radiation in early clinical trials(2, 3).  In addition, SBRT 
used in combination with immunotherapy involving the negative co-stimulatory agonist, 
ipilimumab, resulted in complete remissions in some patients with melanoma(31). It was 
not clear whether daily fractionated radiation that is usually administered over weeks or 
months can synergize with immunotherapy in clinical trials. Preclinical studies have 
demonstrated synergy between the immunostimulation of a hypofractionated radiation 
regimen given over a short duration (5 days) and immunotherapy to treat 4 T1 
tumors(28).  However, extended periods of tumor immunotherapy may kill tumor 
infiltrating immune cells, and the preclinical model used herein was designed to study 
this potentially negative effect of radiotherapy.  
 The single high dose radiation protocol was able to induce T cell immune mediated 
durable remissions in the CT26 tumor. The oligofractionation radiation regimen 
dramatically altered the immunosuppressive microenvironment in the tumors, and within 
14 days the percentage and absolute number per mg of tumor of MDSCs was markedly 
reduced in association with a dramatic increase in the percentage of CD8+ T cells. This 
was confirmed by immunofluorescent staining of tumor tissue sections. The CD8+ T cell 
infiltration began about 6 days after single high dose radiation. A similar pattern of 
infiltration was observed with a single dose of 15 Gy, but the changes were not as robust 
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(Supplementary Figure 2B). The result suggests that effective immunity may be achieved 
with 2 to 3 daily fractions of 15 Gy, an SBRT dose in common clinical use. 
  Mice that developed durable remissions after radiation treatment were resistant to a 
second challenge with CT26 tumors due to development of systemic immunity that 
became potent about 1 month after treatment. Second tumors injected at the time of 
treatment continued to grow while systemic tumor immunity was developing, and the 
evasive microenvironment of second tumors likely prevented anti-tumor T cell 
infiltration. Second tumor evasion may be overcome by enhancing the rapidity and 
potency of tumor immunity by combining SBRT with immunotherapy. On the other 
hand, the lack of late relapse of primary tumors after radiotherapy induced complete 
remissions of the CT26 tumors may be due to the slowly developing tumor immunity. 
The splenic T cells obtained after development of systemic immunity were able to 
transfer anti-CT26 tumor immunity to adoptive hosts, but T cells from untreated mice 
could not. 
 Tumor-bearing RAG-2-/- mice lacking T and B cells and wild type mice depleted of 
CD4+ or CD8+ T cells by monoclonal antibody treatment did not develop remissions after 
radiation. The percentage of MDSCs in the stroma of the tumors in the latter mice 
remained high 14 days after radiation in association with the progressive tumor growth. 
Add-back of T cells to RAG2-/- mice resulted in the reduction of the tumor MDSCs. 
Despite the tumor infiltration of CD8+ T cells but not CD4+ T cells after radiation, 
durable remissions were dependent on CD4+ T cells and their expression of CD40L.  
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  Both the development of remissions and the reduction of MDSCs were dependent on 
IFN-γ, since durable remissions and loss of tumor MDSCs were significantly reduced in 
IFN-γ-/- as compared to wild type hosts. Previous studies have shown that local tumor 
radiation of B16 OVA melanoma cells with a single dose of 15 Gy increases intratumoral 
inflammatory responses by IFN-γ dependent upregulation of VCAM-1 on the 
vasculature, increased expression of chemokines, MIG and IP10, and upregulation of 
MHC class I on tumor cells (55) . In the present study, we found that the source of IFN-γ 
was tumor-infiltrating CD8+ T cells based on adoptive transfer studies using RAG2-/- 
mice that were treated with cyclophosphamide in additon to local tumor radiation (data 
not shown). The results suggest that CD8+ T cell production of IFN-γ controls the 
survival and infiltration of MDSCs in the tumor, and reverses the immunosuppressive 
environment. Furthermore, anti-tumor immune CD8+ T cells can kill MDSCs via their 
production of TNF-α, IFN-γ, or expression of FasL, and thereby reduce MDSC tumor 
infiltration (52-54).  
 The release of HMGB from dying tumor cells can stimulate immunity to tumors by 
activating dendritic cells via the TLR-4 receptor (38). However, TLR-4 was dispensable 
in the model of radiation-induced remissions described here, since tumor remissions were 
obtained in the majority of TLR-4-/- hosts. Tumor remissions were also dependent on the 
CD8+ subset of dendritic cells that have been reported to stimulate CD8+ T cell immunity 
to both tumor and viral antigens via cross priming(49-51).  It is not clear which CT26 
tumor antigens are targeted by the radiation induced CD8+ T cell immunity, since we did 
not observe a significant increase in CD8+T cells staining with the tetramer that identified 
the dominant retroviral antigen, AH-1, (data not shown). 
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  When tumors that had been previously treated with single high dose radiation were 
given conventional fractionated daily dose radiation for 10 days, the therapeutic effect of 
the former treatment was abrogated by the additional irradiation. The additional 
fractionated radiation resulted in a marked decrease in the percentage and absolute 
number (per mg of tumor) of CD8+ T cell tumor infiltrates and in an associated increase 
in MDSCs.  A likely explanation of the latter finding is that the extended radiation killed 
the tumor infiltrating CD8+ T cells(56).  In addition, a recent study showed that 
fractionated radiation can upregulate PDL-1 on tumor cells such that tumors have 
increased resistance to immune eradication(57). This resistance can be overcome by the 
concomitant treatment with anti-PD-1 or anti-PDL-1 antibodies(57) when small (7 to 10 
day) CT26 tumors were studied. However, it is not clear whether the combined treatment 
is effective with the large CT26 tumors (21 day) used in current study.    
 The ability of high dose oligofractionated radiation to stimulate a robust anti-tumor 
immune response may not occur with all tumors.  The success of conventional 
fractionated radiation over several weeks in the induction of complete remissions in 
prostate, and head and neck tumors suggests that T cell infiltration may provide less 
important contribution to control of the latter tumors after radiation. In summary, the 
model depicted in Supplementary Figure 4 shows that the induction of durable tumor 
remissions by high-dose single fraction radiotherapy involves the activation of both 
innate and adaptive immune cells that result in desirable changes in the tumor 
microenvironment.  
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Figure legends 
 
Figure 1. Immunosuppressive tumor microenvironment in CT 26 tumors established 
for 21 days. 
A, Mononuclear cells from day 21 subcutaneous CT26 tumors, spleens from day 21 
tumor-bearing mice, and spleens from normal mice were analyzed for expression of 
CD25, PD-1 and Tim-3 on CD4+ and CD8+ T cells, and for MDSC phenotype cells  
(CD11b+ Gr1hi) and TAM phenotype cells (CD11b+Gr1lo). Percentages of each subset in 
boxes on representative two color analysis panels are shown, and arrows identify gated 
subsets. Staining for CD11b, Gr-1, CD4 and CD8 used a live mononuclear cell gate. B, 
CD8+, CD4+, CD11b Gr-1hi (MDSCs) (n=6) and CD11b Gr-1lo (MΦ) (n=6) cells are 
shown as a mean percentage +/- SE among mononuclear cells in tumor and spleens at day 
21 after tumor implantation, and mean percentage of CD4+CD25+ Foxp3+ cells  shown 
among total CD4+ T cells (n=6). *-p<0.05, ** -p<0.01,***-p<0.001, NS p>0.05. C, 
Representative staining of cultures in which tumor-derived MDSCs were incubated with 
syngeneic splenic T cells loaded with CFSE and with CD3/CD28 beads in vitro for 5 
days. MDSC:Tcell ratio was 1:1.  HTS Transwell-96 well plates with 0.4 µm membranes 
were used for transwell studies.  iNOS (L-NMMA) and L-arginase (nor-NOHA) 
inhibitors were used at 2 different concentrations (0.5 µM and 1.5 µM).  Percentage of 
gated CD8+ T cells that diluted CFSE is shown. D, CFSE dilution by CD8+ T cells is 
shown as a mean percentage +/- SE of triplicate wells. CFSE-labeled T cells were 
cultured with tumor-derived MDSCs in the presence of CD3/CD28 beads. MDSC:T cell 
Research. 
on February 9, 2016. © 2015 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 13, 2015; DOI: 10.1158/1078-0432.CCR-14-2824 
ratios were 1:1, 1:5,1:10. 1:20 and1:40 (n=7). E, CFSE dilution by CD8+ T cells is 
shown as a mean percentage +/- SE of triplicate wells. CFSE-labeled T cells were 
cultured with tumor-derived MDSCs in the presence of CD3/CD28 beads at the 1:1 ratio, 
and L-NMMA and nor-NOHA inhibitors were added in concentrations 0.5 µM or 1.5µM. 
(n=7)  F, Primary CT26 tumors were established at day 0.  Tumor-bearing animals were 
challenged with 5x106 CT26 cells on the opposite flank at day 21. Growth curves of the 
second tumor and fraction of mice with progressive second tumor growth are shown 
(n=5). 
Figure 2. Treatment of advanced CT26 tumors by single high dose radiation leads to 
complete remission, and development of systemic long-term immunity that can be 
adoptively transferred by T cells. 
A, Experimental scheme. CT26 colon tumors were established for 21 days 
subcutaneously and mice received a single dose of local tumor irradiation (LTI). Survival 
after single doses of irradiation 15 (n=8), 20 (n=5) and 30 Gy (n=15) , or without 
radiation (n=9) is shown.  There were significant differences in survival in groups with 
untreated tumors vs tumors treated with 15 Gy (p< 0.01) or in groups treated with 30 Gy 
vs 15 Gy (p< 0.05 ) or by Mantel-Cox test. B, Experimental scheme. Mice with complete 
remissions of 21 day tumors after 30 Gy of LTI (n=12) were selected for this study.  As 
controls, a group of normal mice was vaccinated subcutaneously (s.c.) with 1x106 
irradiated tumor cells (50Gy in vitro) and 30 µg CpG (n=10).  Vaccinated (n=10) or 
irradiated (n=12) mice were challenged with 5x106 of CT26 cells subcutaneously 100-
150 days after treatment. Tumor growth curves, fraction of protected mice and survival 
are shown. There were significant differences in survival of vaccinated or untreated vs 
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irradiated mice (p<0.05). C, Experimental scheme. T cells (6x106) and T cell depleted 
(TCD) bone marrow  cells (1x107) were harvested from mice that were in remissions 
after 30Gy for at least 100 days, and transferred into syngeneic tumor-bearing mice (7 
day tumors) conditioned with 8 Gy of total body irradiation (TBI) (n=5).  T cells and 
TCD bone marrow transfer from untreated mice served as controls (n=5).  Survival for 
100 days is shown. There was a significant difference in survival between groups without 
the transplant procedure (n=9) vs with transplants from LTI donors (p<0.001) (n=5), but 
not with transplants from naïve mice (p>0.1)(n=5). D. Primary CT26 tumors were 
established at day 0. 30 Gy LTI to primary tumor was given at day 21, and mice were 
challenged with 5x106 of CT26 cells on the opposite flank at days 21 (n=5) or 51 (n=5) 
after primary tumor implantation. Growth curves are for second tumors on the 
contralateral flank.There was a significant difference in the fraction without tumor 
growth in groups with LTI challenged at day 21 vs 51 (p<0.05 by Chi Square test). 
Figure 3. Change of balance of tumor-infiltrating cells after 30Gy LTI.   
 A, Mice with 21 day tumors received a single dose of LTI (30 Gy). Tumor infiltrating 
mononuclear cells were analyzed 14 days after LTI completion.  Control tumor-bearing 
mice received no LTI and cells were analyzed at day 35.  Representative stainings of 
CD4+ and CD8+ T cells, MDSCs and TAMs are shown as well as the expression of PD-1 
and Tim-3. B, Immunohistochemistry of tumors at day 35 that were untreated or received 
30 Gy LTI at day 21. Tumor tissue sections were stained with anti-CD3 and anti-CD11b 
antibodies using a two stage procedure. CD11b+-red, CD3+ is green and DAPI staining is 
blue. C, Kinetics of tumor-infiltrating cells after LTI was analyzed at days 1,2,3, 6 and 
14 after LTI that are days 22, 23, 24, 27, and 35 after tumor induction, respectively. 
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Cell subsets (CD11b Gr-1hi, CD11b Gr-1lo, CD11c, CD4+ and CD8+) (n=8) are shown as 
a mean percentage +/- SE among live mononuclear cells in tumor. D, Kinetics of 
tumor-infiltrating cells after LTI was analyzed at days 1,2,3, 6 and 14 after LTI that 
are days 22, 23, 24, 27, and 35 after tumor induction, respectively. Cell subsets 
(CD11b Gr-1hi, CD11b Gr-1lo, CD11c, CD4+ and CD8+) are shown as a mean absolute 
number +/- SE per mg of tumor (n=8). 
 
Figure 4. Curative effect of radiation requires CD4 and CD8 T cells, as well as 
cross-presenting dendritic cells, and is mediated by IFN-γ. 
A, Survival of tumor-bearing animals after 30 Gy LTI depends on CD4+ and CD8+ T 
cells. Wild-type animals with 21 day CT26 tumors received 30Gy LTI (n=14) and anti-
CD8 (n=8) or CD4 (n=5) depleting antibodies. B, Curative effect of LTI depends on 
CD8+dendritic cells. Survival after single dose of 30 Gy LTI at day 21 in Batf3-/- mice 
with (n=9) and without (n=10) add back of purified CD8+ CD11c+ spleen cells is shown. 
The latter cells (5x106) were injected intratumorally within 1 day after irradiation. C, Cell 
subsets (CD11b+Gr-1hi, CD11b+Gr-1lo, CD11c, CD4+ and CD8+) are shown as a mean 
percentage +/- SE among mononuclear cells in tumor at day 14 after LTI in wild-type 
mice with or without CD4+ (n=5) or CD8+T cells (n=5) depletion, in Batf3-/- mice with 
(n=5) and without (n=5) addback of CD8+ CD11c+ cells, and IFN-γ-/- mice (n=5).  D, 
IFN-γ is necessary for curative effect of LTI. IFN-γ-/- (n=13), perforin-/- (n=5) and TNF-
α -/- (n=5), and TLR4-/- (n=14) tumor-bearing mice were used. Survival after single dose 
of LTI at day 21 is shown.  
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Figure 5. Addition of conventional daily fractionated to single high dose radiation 
results in decreased survival of tumor-bearing mice and metastatic spread of the 
tumor.  
A, Balb/c mice with 21 d CT 26 tumors received a single dose 30 Gy LTI (n=15), 
fractionated LTI 3Gy daily for 10 days (n=8), and combined regimen single dose 30Gy 
LTI on day 21 and fractionated 3Gyx10 started on day 24 (n=8). Survival of tumor-
bearing mice shown. There were significant differences in survival in groups with LTI 
30Gy vs fractionated or combined regimens (p< 0.01) by Mantel-Cox test. B, Cell 
subsets (CD8+, CD4+, CD11b Gr-1hi and CD11b Gr-1lo) are shown as a mean percentage 
+/- SE among live mononuclear cells in tumor at day 35 after tumor implantation (day 14 
after LTI started) (n=5). C, H&E staining of the lungs (day 14 after LTI) of tumor-
bearing animals that received combined LTI regimen (30Gy+3Gx10). D, Tumor growth 
curves and fraction of mice that survived at least 100 days are shown after single dose of 
30Gy or combined regimen of 30Gy+3Gyx10. E, Cell subsets (CD8+, CD4+, CD11b Gr-
1hi and CD11b Gr-1lo) are shown (after a single dose of 30 Gy (n=5) or combined 
regimen of 30 Gy+3Gyx10) (n=5) as a mean number +/- SE per mg of tumor at day 35 
after tumor implantation (day 14 after LTI started). 
 
Figure 6.  Studies with the MC38 colon tumor. Curative effect of single high dose 
radiation requires CD40L expression on CD4+ T cells. 
A.MC38 colon tumors were established for 21 days subcutaneously in C57/B6 mice or 
C57B6 RAG2-/- mice, and the mice received a single dose of LTI 30Gy. Survival after 
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single doses of irradiation 30 Gy (n=17), or without radiation is shown (n=8).  There 
were significant differences in survival in WT mice treated with 30 Gy vs RAG2-/- 
treated group (p< 0.05), or  WT untreated group (p<0.01) by Mantel-Cox test. B, Cell 
subsets (CD8+, CD4+, CD11b+ Gr-1hi and CD11b+ Gr-1lo) are shown as a mean 
percentage +/- SE among mononuclear cells in tumor at day 35 after tumor implantation 
in untreated WT (n=5) vs mice treated with LTI 30Gy (n=5) at day 21. C, MC38 tumors 
were established for 21 day. Survival of TLR4-/- (n=7), FasL-/- (n=12), and CD40 L-/- 
(n=10) tumor-bearing mice that received 30Gy LTI at day mice is shown. Survival of 
unirradiated wild type and gene inactivated mice given MC38 tumors was not 
significantly different (data not shown). D, Scheme: 6x106 of CD4+ T cells from CD40L-
/- or WT mice and 2x106 of CD8+ from wild-type mice were transferred into RAG2-/- 
mouse within 6 hours after they received 3 Gy total body irradiation. 6 weeks after TBI, 
MC38 tumors were established subcutaneously. MC38 tumors received 30 Gy LTI at day 
21. E, Survival of MC38 tumor-bearing RAG2-/- mice or mice reconstituted by CD40L-/- 
CD4+ (n=10) or CD4 WT T cells (n=7) and CD8+ WT T cells. All mice received 30 Gy 
LTI at day 21. F, Cell subsets (CD8+, CD4+, CD11b+ Gr-1hi, CD11c+ and CD11b+ Gr-1lo) 
are shown as a mean percentage +/- SE live among mononuclear cells in tumors in 
RAG2-/- mice reconstituted with CD40L-/- CD4+ T cells and CD8+ WT T cells two weeks 
after 30 Gy LTI (n=5). 
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